Skip to Main Content
 

Global Search Box

 
 
 
 

ETD Abstract Container

Abstract Header

Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy

Abstract Details

2016, Master of Science, Ohio State University, Biomedical Sciences.
Sorafenib therapy has been shown to have only a small clinical benefit for liver cancer patients. There is an urgent needed to develop new therapeutic strategies for the treatment of advanced stage HCC. In this report, we screened several repurposed therapeutics in order to identify synergistic drug combinations. We demonstrate that the combination of 2-deoxy-glucose and sorafenib drastically inhibit HCC cell viability in Hep3B, Huh7 and sorafenib resistant Huh7 cells. Cell cycle analysis revealed that this therapeutic combination induced complete G0/G1 arrested HCC cells. Our studies suggest that this cell-cycle arrest is due to the depletion of cellular ATP. Overall, this report provides strong evidence for the clinical potential of sorafenib + 2-deoxyglucose combination therapy.
Samson Jacob, PhD (Advisor)
Kalpana Ghoshal, PhD (Committee Member)
30 p.

Recommended Citations

Citations

  • Reyes, R. (2016). Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086

    APA Style (7th edition)

  • Reyes, Ryan. Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy. 2016. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086.

    MLA Style (8th edition)

  • Reyes, Ryan. "Sorafenib and 2-Deoxyglucose: The Future of Hepatocellular Carcinoma Therapy." Master's thesis, Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461275086

    Chicago Manual of Style (17th edition)